Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 111,800 shares, a decrease of 21.1% from the September 30th total of 141,700 shares. Based on an average trading volume of 560,200 shares, the days-to-cover ratio is presently 0.2 days. Approximately 11.9% of the shares of the stock are sold short.

Allarity Therapeutics Price Performance

Shares of Allarity Therapeutics stock opened at $1.55 on Wednesday. The business has a 50 day simple moving average of $2.88 and a two-hundred day simple moving average of $11.64. Allarity Therapeutics has a 12 month low of $1.32 and a 12 month high of $666.00.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings data on Monday, August 5th. The company reported ($3.30) EPS for the quarter. On average, research analysts predict that Allarity Therapeutics will post -78.08 EPS for the current fiscal year.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.